Angioblast Systems, Inc.

Angioblast Systems, Inc. is a United States-based biotechnology company committed to the development of novel treatments for cardiac, vascular, and eye conditions.  Mesoblast has acquired 39.2% equity in Angioblast.

Angioblast's lead products are based on commercialisation of a unique adult stem cell technology using adult Mesenchymal Precursor Cells, capable of regulating blood vessel growth critical for the treatment of ischemic heart disease and macular degeneration/diabetic eye disease.

Mesoblast and Angioblast are jointly developing and commercialising the core technology in as short a timeframe as possible.

Mesoblast intends to drive shareholder value by engaging corporate partners at various critical stages in its product development process.

About us
Organisation
Executive management
Scientific Advisory Board
Corporate Governance